From a murine breast cancer cell line, 4T1, we established a subclone, 4T1.3, which consistently metastasizes to bone upon its injection into the mammary fat pad. 4T1.3 clone exhibited similar proliferation rate and migration capacity as the parental clone. However, the intra-bone injection of 4T1.3 clone caused larger tumors than that of the parental cells, accompanied with increases in fibroblast, but not osteoclast or osteoblast numbers. 4T1.3
Results

4T1-derived 4T1.3 clone exhibited enhanced capacity to metastasize to bone.
We obtained 4T1.3 clone from a mouse triple-negative breast cancer cell line, 4T1 cells, by repetitive selection of the cells which survived in the bone cavity after the injection into MFP (Fig. 1A) . 4T1.3 clone metastasized to bone with high frequency when injected into MFP, in contrast with the parental 4T1.0 clone, which did not cause bone metastasis (Fig. 1B and S1A). Under in vitro anchorage-dependent culture conditions, 4T1.0 and 4T1.3 clones exhibited similar proliferation and survival rates (Fig. 1C) . Moreover, both clones grew at a similar rate in MFP (Fig. 1D ) and formed metastasis foci in lungs at a similar frequency ( Fig. S1B ), when injected into MFP. In a short-term migration assay reflecting the extravasation step, both clone migrated to BM with similar efficiency (Fig. 1E) . On the contrary, 4T1.3 clone formed a larger tumor focus than 4T1.0 clone, when injected into bone (Fig. 1F, 1G , and Fig. S2 ). Thus, the higher capacity of 4T1.3 clone to metastasize to bone cavity, can be ascribed mainly to its greater ability to grow and/or survive in the bone cavity.
4T1.3 clones exhibited a mesenchymal-like phenotype with resistance to anoikis.
To determine the molecular mechanisms underlying the higher capacity of 4T1.3 clone to metastasize to bone, we systematically analyzed gene expression patterns by DNA microarray. Gene set enrichment analysis (GSEA) detected enrichment in stem cell-related genes in the 4T1.3 clone ( Fig. 2A ). 4T1.3 clone consistently expressed a higher level of CD44 than 4T1.0 clone (Fig. 2B ). 4T1.3 clone displayed a round shape in contrast to 4T1.0 clone with an elongated form (Fig. 1A) . Moreover, E-cadherin expression was depressed while N-cadherin and Twist expression was reciprocally enhanced in 4T1.3 clone, compared with 4T1.0 clone (Fig. 2C) . Furthermore, under anchorage-independent conditions, 4T1.3 clone survived better than 4T1.0 clone (Fig. 2D) . Thus, 4T1.3 clone gained resistance to anoikis together with some of the characteristics of stem and/or mesenchymal cell phenotypes.
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Involvement of enhanced CCL4 expression in 4T1.3 clone in bone metastasis process
Given the potential involvement of chemokines in metastasis [14] , we analyzed the DNA microarray data by focusing on the expression of chemokine-related molecules. We observed that the expression of several chemokines was enhanced in 4T1.3 clone, compared with 4T1.0 clone (Fig. S3) . qRT-PCR analysis unraveled enhanced expression of CCL4 (∆∆Ct: -4.808±0.212) and to a lesser degree, CCL3 (∆∆Ct: -2.897±0.196) but not CCL5 mRNA in 4T1.3 clone, compared with 4T1.0 clone (Fig. 3A) . Consistent with that, 4T1.3 clone constitutively expressed CCL4, but not CCL3, protein whereas both chemokines were barely detected in 4T1.0 clone (Fig. 3B) . However, the expression of CCR5, a specific high-affinity receptor for CCL4, was not detected at the mRNA and protein levels in 4T1.3 clone ( Fig. 3C and 3D ). This contrasts with the previous report that murine breast cancer cells expressed CCR5 [15] . On the other hand, the expression of CCR1, a high-affinity receptor for CCL3 and CCL5 but not CCL4, was enhanced in 4T1.3 clone compared with 4T1.0 clone ( Fig. 3C and 3D ). We next examined the effect of abrogating CCL4 expression on the bone metastasis capacity of the 4T1.3 clone. CCL4 shRNA treatment did selectively reduce CCL4 expression in 4T1.3 clone (Fig. S4 ). CCL4 shRNA-treated 4T1.3 clone exhibited reduced tumor formation in bone, when injected into either MFP (data not shown) or the bone cavity, compared with scrambled (scr)-shRNA-treated 4T1.3 clone (Fig. 3E ).
CCL4 shRNA consistently did not reduce the in vitro cell proliferation rates, resistance to anoikis (Fig. 3F) , and short-term migration capacity of 4T1.3 clone (Fig. 3G) . Moreover, CCL4-shRNA treatment failed to reduce the expression of stem cell markers, CD24 and CD44 (Fig. 3H) , suggesting that the stem cell phenotype was not essential for bone metastasis, in contrast with the previous report of a murine breast cancer cell line with an ability to metastasize to lung [16] . CCL4 shRNA treatment also did not reduce the mRNA expression of mesenchymal markers, N-cadherin and Twist (Fig. 3I) . Given the lack of CCR5 expression in 4T1 cells, cancer cell-derived CCL4 could act in rather a paracrine than an autocrine manner, to promote bone metastasis.
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Involvement of CCR5-expressing non-cancerous cells in bone metastasis process
The absence of CCR5 expression by 4T1.3 clone prompted us to investigate the roles of CCR5-expressing non-cancerous cells in bone metastasis process. Indeed, 4T1.3 clone formed smaller tumor focus in CCR5 KO mice compared with WT mice, when injected into the bone cavity ( Fig. 4A and S5A) . In order to exclude the effects of persistent CCR5 deficiency from birth, we transduced the gene of tRANTES/CCL5, with a potent CCR5 inhibitory activity, before intra-bone injection of 4T1.3 clone. This treatment efficiently reduced intra-bone tumor formation by 4T1.3 clone injection ( Fig. 4B and S5B) . Moreover, 4T1.3 clone exhibited markedly reduced tumor formation in WT mice transplanted with CCR5 KO mouse-derived BM cells compared with WT mice transplanted with WT-derived BM cells (Fig. 4C, S6A , and S6B). These observations suggest that CCR5-expressing non-cancerous cells in bone, particularly radio-sensitive ones, were involved in tumor formation induced by intra-bone injection of 4T1.3 clone.
Increase in type I collagen-positive cells but neither OCs nor OBs after intra-bone injection of 4T1.3 clone
Presumed crucial involvement of OCs and OBs in bone metastasis stimulated us to examine the numbers of these cells in BM. Unexpectedly, CD51-positive OC numbers in BM were similar in mice injected with 4T1.0 and 4T1.3 clones and did not decrease when CCL4
shRNA-treated 4T1.3 clone was injected ( Fig. 4D and S7 Among the growth factors that we examined, CTGF/CCN2 mRNA expression was selectively enhanced in 4T1.3-injected mice (Fig. 5B) . Moreover, type I collagen and CTGF/CCN2 mRNA expression was coincidentally detected in a CCR5-positive population of BM cells in mice which received intra-bone injection with 4T1.3 clone (Fig. 5C) . A double-color immunofluorescence analysis consistently detected CTGF/CCN2 expression in type I collagen-positive cells (Fig. 5D ). Furthermore, CTGF/CCN2 expression was enhanced in BM of WT mice injected with 4T1.3 clone, but not those injected with CCL4-shRNA-treated 4T1.3 clone or those injected with 4T1.0 clone (Fig. 5E ). An analysis using BM chimeric mice further demonstrated that CTGF/CCN2 expression was selectively increased in 4T1.3-injected mice whose BM cells were derived from WT mice (Fig. 5E ).
Thus, increased tumor formation together with increased type I collagen-positive cell numbers and enhanced CTGF/CCN2 expression in bone, occurred upon intra-bone injection of CCL4-overexpressing 4T1.3 clone. In addition, CCL4 induced a fibroblast cell line, NIH3T3, to express CTGF/CCN2, type I collagen, and α-SMA (Fig. 6A ), and to proliferate Sasaki et al. 11 ( Fig. 6B) . Finally, CTGF increased in vitro cell proliferation of 4T1.3 clones under anchorage-independent and hypoxic conditions, resembling the conditions in the bone cavity (Fig. 6C) . However, these properties were not observed on 4T1.0 clone (Fig. 6C) . (Fig.6D) , suggesting that CCL4 can act as a pro-metastatic mediator.
Discussion
Metastasis, spread of cancer, is based on a multi-step process consisting of tumor growth at a primary site, intravasation, survival in the circulation, extravasation, and We detected selective CTGF/CCN2 expression by fibroblasts. CTGF/CCN2 was originally identified as a factor with a mitogenic activity for fibroblasts but subsequent studies revealed that it has a variety of actions on myriad types of cells besides fibroblasts ) 1125-1131.
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Alexa Fluor 488-labeled hamster anti-mouse podoplanin antibodies (BioLegend), FITC-labeled rat anti-mouse CD3, PerCP Cy5.5-labeled rat anti-mouse CD45 and PE-labeled rat anti-mouse CD51 antibodies (eBioscience), APC-labeled rat anti-mouse CD11b, PE-labeled rat-anti mouse CD44, APC-labeled rat anti-mouse B220, PE-labeled rat anti-mouse RANKL/TRANCE and rat anti-Ly6G antibodies (BD Biosciences), rat anti-mouse F4/80 antibody (Serotec), rabbit anti-mouse type I collagen antibody (Abcam).
DNA microarray analysis
Total RNAs were extracted from 4T1.0 or 4T1.3 cells using RNeasy Mini Kit (Qiagen), and their quality was confirmed by using an Agilent 2100 Bioanalyzer (Agilent Technologies).
All samples showed RNA Integrity Numbers (RIN) of more than 8.0 and were subjected to microarray analysis according to the manufacturer's instructions. In brief, RNA samples were labeled using the Low Input Quick Amp Labeling Kit (Agilent Technologies).
Labeling of 100 ng of total RNA was performed using cyanine 3-CTP. Hybridization was performed using the Gene Expression Hybridization Kit (Agilent Technologies). cRNA samples (600 ng) were subjected to fragmentation (30 min at 60°C) and then hybridized on with DAPI for 10 min at room temperature. Immunofluorescence was assessed by using a
Keyence BZ-X700 (Keyence Japan).
Immunohistochemical analyses of mouse bone tissues
Resected mouse tibiae were fixed in Tissue-Tek Ufix (Sakura Fine Technical Co.) for 2 days and were embedded in paraffin. The sections were cut at 3 μm thickness and were 
Flow cytometric analysis of BM cells
For detection of OCs and OBs, single cell suspensions were prepared from tibial bones, which were treated sequentially by mincing with scissors, incubation with RPMI 1640 containing 1 mg/ml collagenase type I, 1 mg/ml dispase and 40 µg/ml DNase I for 1 hr at 37°C and erythrocyte depletion by using ammonium chloride lysing buffer. The corresponding populations consisted of more than 95 % purity (data not shown).
In vitro cell proliferation assay
Either 4T1.0 or 4T1.3 cell suspensions were added to a 100-mm dish at a cell density of 20 
In vivo truncated RANTES gene transduction
Either truncated (t)RANTES/CCL5-pLIVE or control vector were i.v. injected by using
TransIT-EE Hydrodynamic Delivery Solution (Mirus Corporation) as described previously [2] . Two weeks later, the animals were subjected to intra-bone injection of 4T1.3 clone
Short-term migration assay
4T1.0 or 4T1.3 clones were labeled with PKH67 (Sigma-Aldrich), according to the manufacture's protocol. At 18 hours after irradiation with 9 Gy, the labeled tumor cells (3 x 6 cells) were injected i.v. into WT mice. Three hours later, mice were sacrificed to remove tibiae. The tibial bones were flushed with the complete medium to obtain total bone marrow (BM) cells. The ratio of PKH67-positive cells migrated to BM was measured to determine the relative homing efficiency on a FACSCanto System II (BD Biosciences).
Treatment with shRNA
Lentivirus expressing MISSION shRNAs targeting for mouse CCL4 (TRCN425182 and TRCN441627) and scrambled (scr) RNAs (Nontarget; SHC002) were prepared by using pLK01-puro (Sigma-Aldrich) according to the manufacturer's instructions. The resultant shRNA preparations were transduced into 4T1.3 cell lines using JetPRIME DNA & siRNA transfection reagent (Polyplus transfection). Then, the cells were cultured in medium containing puromycin (2 µg/ml) for 2 weeks, to obtain stable clones.
Clinical database analysis
Relapse-free survival (GSE1379) was evaluated by analyzing the data deposited in the Prognoscan [3] (http://www.abren.net/PrognoScan/) and was shown using Kaplan-Meier curve. The cut-off point was set to divide the patients into 2 groups, high and low CCL4-expressing groups, as described previously [4] .
qRT-PCR analysis
Total RNAs were extracted from the cell lines or the tumors by using RNeasy Mini Kit (Qiagen) and subjected to qRT-PCR by using the primers listed in Table S1 , as described previously [2] . Expression levels of the target genes were analyzed through the comparative threshold cycle method (ΔΔCT). The GAPDH gene or hypoxanthine guanine phosphoribosyltransferase (HPRT) were used as an internal control.
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